The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Racial disparities in access after regulatory surveillance of benzodiazepines.
Sallie-Anne Pearson; Stephen Soumerai; Connie Mah; Fang Zhang; Linda Simoni-Wastila; Carl Salzman; Leon E Cosler; Thomas Fanning; Peter Gallagher; Dennis Ross-Degnan (Profiled Author: Linda Jean Simoni-Wastila)
Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, Massachusetts 02215, USA.
Archives of internal medicine 2006;166(5):572-9.
BACKGROUND: We examined the effects of a prescription-monitoring program on benzodiazepine access among Medicaid enrollees living in neighborhoods of different racial composition. METHODS: We used interrupted time series and logistic regression to analyze data from noninstitutionalized persons aged 18 years or older (N = 124 867) enrolled continuously in New York Medicaid 12 months before and 24 months and 7 years after initiation of the program. We used census data to identify the racial composition of the neighborhoods. Outcome measures were nonproblematic use (short term, within dosing guidelines), potentially problematic use (>120 days' use or more than twice the recommended dose), and pharmacy hopping (filling prescriptions for the same benzodiazepine in different pharmacies within 7 days). RESULTS: There was a sudden, sustained reduction in benzodiazepine use in all the neighborhoods after the program's introduction. Despite the lowest rates of baseline use, enrollees in predominantly (> or = 75%) black neighborhoods experienced the highest rates of discontinuation after introduction of the program. This difference remained 7 years after policy initiation. Compared with white participants, black participants were more likely to discontinue nonproblematic (odds ratio, 1.78; 95% confidence interval, 1.47-2.17) and potentially problematic (odds ratio, 1.77; 95% confidence interval, 1.45-2.17) benzodiazepine use, after adjusting for sex, eligibility status, neighborhood poverty, and baseline use. The program almost completely eliminated pharmacy hopping in all racial groups, although less among white participants (82.6%) vs black participants (88.7%). CONCLUSIONS: A systematic benzodiazepine prescription-monitoring program reduced inappropriate prescribing, with a stronger effect in predominantly black neighborhoods despite lower baseline use. The policy may have resulted in an unintended decrease in nonproblematic use that disproportionately affects black populations.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Dennis Ross-Degnan; Linda Simoni-Wastila; Jeffrey S Brown; Xiaoming Gao; Connie Mah; Leon E Cosler; Thomas Fanning; Peter Gallagher; Carl Salzman; Richard I Shader; et al.International journal of psychiatry in medicine 2004;34(2):103-23.
Linda Simoni-Wastila; Dennis Ross-Degnan; Connie Mah; Xiaoming Gao; Jeffrey Brown; Leon E Cosler; Thomas Fanning; Peter Gallagher; Carl Salzman; Stephen B SoumeraiClinical therapeutics 2004;26(2):322-36.
Julie M Zito; Daniel J Safer; Satish Valluri; James F Gardner; James J Korelitz; Donald R MattisonJournal of child and adolescent psychopharmacology 2007;17(2):195-203.
Appears in this Publication
Author of this Publication